CYP2C19 Genotyping to Guide Antiplatelet Therapy for the Secondary Prevention of Lacunar Strokes

Affiliations

• ¹ From the Department of Clinical Neurological Sciences (L.A.S.), Schulich School of Medicine and Dentistry, Heart & Brain Laboratory (L.A.S.), Departments of Epidemiology and Biostatistics and Anatomy and Cell Biology (L.A.S.), Schulich School of Medicine and Dentistry, Robarts Research Institute (L.A.S.), Western University; Lawson Health Research Institute (L.A.S.), London, Ontario, Canada; Department of Neurology (G.A.D.), Melbourne Brain Centre, The Royal Melbourne Hospital; and Faculty of Medicine Dentistry and Health Sciences (G.A.D.), The University of Melbourne, Parkville, Australia. [email protected].
• ² From the Department of Clinical Neurological Sciences (L.A.S.), Schulich School of Medicine and Dentistry, Heart & Brain Laboratory (L.A.S.), Departments of Epidemiology and Biostatistics and Anatomy and Cell Biology (L.A.S.), Schulich School of Medicine and Dentistry, Robarts Research Institute (L.A.S.), Western University; Lawson Health Research Institute (L.A.S.), London, Ontario, Canada; Department of Neurology (G.A.D.), Melbourne Brain Centre, The Royal Melbourne Hospital; and Faculty of Medicine Dentistry and Health Sciences (G.A.D.), The University of Melbourne, Parkville, Australia.